Mark S. Blumenkranz, MD, and Allen C. Ho, MD, fielded a remarkable team of key opinion leaders and entrepreneurs for a valuable, retina-focused program.
A dozen innovation companies opened their playbooks to reveal novel treatments and new technologies at the cutting edge of retina care. See recordings of the company showcases here.
Program Agenda
Welcome!
8:00 – 8:05 a.m.
Pacific Time
Mark S. Blumenkranz, MD and Allen C. Ho, MD
Innovative Treatments Generating Opportunities for Retina
8:05 – 9:00 a.m.
Get an inside look at next generation interventions for photoreceptor survival in retinal detachment, age related macular degeneration, and the current and future promise of anti-sense oligonucleotide gene therapy.
Moderator: Allen C. Ho, MD
Company Showcases
-
ONL Therapeutics: David Esposito, CEO
-
LumiThera: Clark Tedford, President & CEO
-
Annexon Biosciences: Sanjay Keswani, MBBS, Chief Medical Officer
-
Lineage Cell Therapeutics: Gary Hogge, PhD, Sr.VP, Clinical and Medical Affairs
-
ProQR: Aniz Girach, MD, Chief Medical officer
Panel Experts:
Robert Avery, MD
Julia A. Haller, MD
Namrata Saroj, OD
Digital Imaging and AI in Clinical Trials and Practice
9:00-9:55 a.m.
Meet the companies innovating on digital ophthalmology products that have become critical to the modern retinal practice. Our panel experts will explore the technical challenges, regulatory and reimbursement considerations, workflow impact, ethics, data ownership and security.
Moderator: Mark S. Blumenkranz, MD
Company Showcases
-
Beyeonics: Ron Schneider, CEO
-
Digital Diagnostics: Michael Abràmoff, MD, Founder
-
Eyenuk: Kaushal Solanki, Founder & CEO
-
Notal Vision: Kester Nahen, CEO
-
Ocutrx Vision Technologies: Michael A. H. Freeman, CEO/CTO
-
Verana Health: Hylton Kalvaria, Chief Business Officer
Panel Experts:
Emily Y. Chew, MD, NEI
Malvina B. Eydelman, MD, FDA
Paul Hallen, Alcon
Angelo Rago, ZEISS
George A. Williams, MD, Beaumont Eye Institute
Closing Remarks
9:55-10:00 a.m.
Mark S. Blumenkranz, MD and Allen C. Ho, MD